As filed with the Securities and Exchange Commission on April 7, 2022

 

Registration No. 333-         

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

ALPHA TAU MEDICAL LTD.

(Exact name of registrant as specified in its charter)

 

 

 

Israel   Not Applicable
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)   Identification Number)

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605 

+972 (3) 577-4115

(Address of Principal Executive Offices) (Zip Code)

 

Alpha Tau Medical Ltd. 2016 Share Incentive Plan 

Alpha Tau Medical Ltd. 2021 Share Incentive Plan

Alpha Tau Medical Ltd. 2021 Employee Share Purchase Plan 

(Full Title of the Plan)

 

Alpha Tau Medical, Inc.

1 Union Street 3rd Floor 

Lawrence, MA 01840

(Name and Address of Agent for Service)

 

(833) 455-3278 

(Telephone Number, Including Area Code, of Agent for Service)

 

 

 

Copies to:

Nathan Ajiashvili

Joshua G. Kiernan

Michael J. Rosenberg

Latham & Watkins LLP

1271 Avenue of the Americas

New York, New York 10020

Tel: (212) 906-1200

  

Shachar Hadar

Yoav Nahir

Matthew Rudolph

Meitar | Law Offices

16 Abba Hillel Silver Rd.

Ramat Gan 5250608, Israel

Tel: +972 (3) 610-3100

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      ¨ Accelerated filer                   o
Non-accelerated filer    þ Smaller reporting company o

 

      Emerging growth company þ
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

  

 

 

 

 

 

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The following documents filed by the Registrant with the Commission are incorporated herein by reference:

 

(a) The Registrant’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on March 28, 2022 pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and

 

  (b) The description of the Registrant’s ordinary shares contained in the Registrant’s registration statement on Form 8-A (File No. 001-41316), filed by the Registrant with the SEC under Section 12(b) of the Exchange Act on March 7, 2022 including any amendments or reports filed for the purpose of updating such description

 

In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and certain Reports on Form 6-K furnished by the Registrant to the Commission (which indicate that they are incorporated herein by reference), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any document or portion thereof, whether specifically listed above or to be filed in the future, that is not deemed “filed” with the Commission.

 

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

2

 

 

Item 4. Description of Securities.

 

Not applicable.

 

Item 5. Interests of Named Experts and Counsel.

 

Not applicable.

 

Item 6. Indemnification of Directors and Officers.

 

Under the Israeli Companies Law, 5759–1999 (the “Companies Law”), a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability, in whole or in part, for damages caused as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. An Israeli company may not exculpate a director from liability arising out of a prohibited dividend or distribution to shareholders.

 

An Israeli company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed as an office holder, either in advance of an event or following an event, provided a provision authorizing such indemnification is contained in its articles of association:

 

  •   a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator’s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the above mentioned events and amount or criteria;

 

  •   reasonable litigation expenses, including legal fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such

 

  •   as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction;

 

  •   reasonable litigation expenses, including legal fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a

 

  •   third-party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent; and

 

  •   expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.

 

An Israeli company may insure an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the company’s articles of association:

 

  •   a breach of the duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;

 

  •   a breach of the duty of care to the company or to a third-party, including a breach arising out of the negligent conduct of the office holder;

 

  •   a financial liability imposed on the office holder in favor of a third-party;

 

3

 

 

  •   a financial liability imposed on the office holder in favor of a third-party harmed by a breach in an administrative proceeding; and

 

  •   expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.

 

An Israeli company may not exculpate, indemnify or insure an office holder against any of the following:

 

  •   a breach of the duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;

 

  •   a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;

 

  •   an act or omission committed with intent to derive illegal personal benefit; or

 

  •   a fine, monetary sanction or forfeit levied against the office holder.

 

Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors (and, with respect to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the Companies Law, the insurance of office holders does not require shareholder approval and may be approved by only the compensation committee if the engagement terms are determined in accordance with the company’s compensation policy which was approved by the shareholders by the same special majority required to approve a compensation policy, provided that the insurance policy is on market terms and the insurance policy is not likely to materially impact the company’s profitability, assets or obligations.

 

Our amended and restated articles of association allow us to exculpate, indemnify and insure our office holders for any liability imposed on them as a consequence of an act (including any omission) which was performed by virtue of being an office holder. Our office holders are currently covered by a directors’ and officers’ liability insurance policy.

 

We have entered into agreements with each of our directors and executive officers exculpating them in advance, to the fullest extent permitted by law, from liability for damages caused as a result of a breach of duty of care, and undertaking to indemnify them to the fullest extent permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on our activities, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.

 

The maximum indemnification amount set forth in such agreements is limited to an amount equal to the highest of $100 million, 25% of our total shareholders’ equity as reflected in our most recent consolidated financial statements prior to the date on which the indemnity payment is made and 10% of our total market cap calculated based on the average closing price the Registrant’s Ordinary Shares over the 30 trading days prior to the actual payment, multiplied by the total number of our issued and outstanding shares as of the date of the payment (other than indemnification for an offering of securities to the public, including by a shareholder in a secondary offering, in which case the maximum indemnification amount is limited to the gross proceeds raised by us and/or any selling shareholder in such public offering). The maximum amount set forth in such agreements is in addition to any amount paid (if paid) under insurance and/or by a third-party pursuant to an indemnification arrangement.

 

We have purchased and currently intend to maintain insurance on behalf of each and every person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

 

In the opinion of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.

 

Item 7. Exemption from Registration Claimed.

 

Not applicable.

 

4

 

 

Item 8. Exhibits.

 

        Incorporation by Reference
Exhibit No.   Description   Form   File No.   Exhibit No.   Filing Date   Filed /
Furnished
4.1   Amended and Restated Articles of Association of Alpha Tau Medical Ltd.   20-F   001-41316   1.1   March 28, 2022    
4.2   Specimen Ordinary Share Certificate   F-4   333-258915   4.5   January 5, 2022    
5.1   Opinion of Meitar | Law Offices.                   *
23.1   Consent of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, independent registered accounting firm                   *
23.2   Consent of Meitar | Law Offices (included in Exhibit 5.1).                    
24.1   Power of Attorney (included on the signature page of the Registration Statement).                    
99.1   2016 Share Incentive Plan of Alpha Tau Medical Ltd.   F-4   333-258915   10.7   August 18, 2021    
99.2   2021 Share Incentive Plan of Alpha Tau Medical Ltd.   F-4   333-258915   10.8   December 1, 2021    
99.3   2021 Employee Share Purchase Plan of Alpha Tau Medical   F-4   333-258915   10.9   December 1, 2021    
107   Filing Fee Table                   *
                         

 

Item 9. Undertakings.

 

(a)       The undersigned Registrant hereby undertakes:

 

  (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

 

  (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

  (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in this Registration Statement; and

 

  (iii) To include any material information with respect to the Plans not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

 

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

5

 

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

6

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Jerusalem, Israel, as of April 7, 2022.

 

  ALPHA TAU MEDICAL LTD.
     
  By: /s/ Uzi Sofer
   

Name: Uzi Sofer

Title: Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Uzi Sofer and Raphi Levy, and each of them, individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

 

Signature Title  Date 
        
/s/ Uzi Sofer  Chief Executive Officer & Chairperson  April 7, 2022 
Uzi Sofer  (Principal Executive Officer)    
        
/s/ Raphi Levy  Chief Financial Officer  April 7, 2022 
Raphi Levy  (Principal Financial Officer and Principal Accounting Officer)    
        
/s/ Ruth Alon  Director  April 7, 2022 
Ruth Alon       
        
/s/ Michael Avruch  Director  April 7, 2022 
Michael Avruch       
        
/s/ S. Morry Blumenfeld, Ph.D.  Director  April 7, 2022 
S. Morry Blumenfeld, Ph.D.       
        
/s/ Meir Jakobsohn  Director  April 7, 2022 
Meir Jakobsohn       
        
/s/ Alan Adler  Director  April 7, 2022 
Alan Adler       
        
/s/ Gary Leibler  Director  April 7, 2022 
Gary Leibler       
        
/s/ Peter Melnyk  Director  April 7, 2022 
Peter Melnyk       
        
/s/ David Milch  Director  April 7, 2022 
David Milch       

 

7

 

 

AUTHORIZED REPRESENTATIVE

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Alpha Tau Medical Ltd. has signed this registration statement on April 7, 2022.

 

  ALPHA TAU MEDICAL, INC.
     
  By:

/s/ Uzi Sofer

    Name: Uzi Sofer
    Title: President and Director

 

8

 

 

Exhibit 5.1

 

 

 

April 7, 2022

 

Alpha Tau Medical Ltd.

Kiryat HaMada St. 5

Jerusalem, 9777605

Israel

            

 

RE: Registration on Form S-8

 

Ladies and Gentlemen:

 

We have acted as Israeli counsel to Alpha Tau Medical Ltd., an Israeli company (the “Company”), in connection with its filing of a registration statement on Form S-8 on or about April 7, 2022 (the “Registration Statement”), under the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration of 23,907,795 of the Company’s ordinary shares, no par value (the “Ordinary Shares”), which may be issued under the Alpha Tau Medical Ltd. 2016 Share Incentive Plan, Alpha Tau Medical Ltd. 2021 Share Incentive Plan and Alpha Tau Medical Ltd. 2021 Employee Share Purchase Plan (each a “Plan” and collectively the “Plans”).

 

In our capacity as counsel to the Company, we have examined originals or copies, certified or otherwise identified to our satisfaction, of the Company’s (i) Amended and Restated Articles of Association (the “Articles”), (ii) the Plans, (iii) resolutions of the Company’s board of directors and (iv) other statements of corporate officers and other representatives of the Company and other documents provided to us by the Company as we have deemed necessary or appropriate as a basis for this opinion. In such examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals and the conformity with the original documents of all documents submitted to us as copies or facsimiles. As to any facts material to this opinion, to the extent that we did not independently establish relevant facts, we have relied on certificates of public officials and certificates of officers or other representatives of the Company. We have also assumed the truth of all facts communicated to us by the Company and that all consents, minutes and protocols of meetings of the Company’s board of directors, which have been provided to us, are true and accurate and prepared in accordance with the Company’s Articles and all applicable laws. In addition, we have assumed that the Company will receive the full consideration for the Ordinary Shares (which may consist, in part or in full, of services performed for the Company).

 

We are admitted to practice law in the State of Israel and the opinion expressed herein is expressly limited to the laws of the State of Israel.

 

On the basis of the foregoing, we are of the opinion that the Ordinary Shares being registered pursuant to the Registration Statement, when issued and paid for in accordance with the respective Plan, pursuant to agreements with respect to the respective Plan and, as the case may be, pursuant to the terms of the awards that have been or may be granted under the respective Plan, will be validly issued, fully paid and non-assessable.

 

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this opinion and such consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the Securities and Exchange Commission promulgated thereunder or Item 509 of Regulation S-K promulgated under the Securities Act.

 

 

- 2 -

 

This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.

 

  Very truly yours,
   
  /s/ Meitar | Law Offices

 

 

 

 

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2016 Share Incentive Plan of Alpha Tau Medical Ltd. and the 2021 Share Incentive Plan of Alpha Tau Medical Ltd. of our report dated March 28, 2022 with respect to the consolidated financial statements of Alpha Tau Medical Ltd., included in its Annual Report (Form 20-F) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.

 

    /s/ KOST, FORER, GABBAY & KASIERER
A Member of Ernst & Young Global

 

Tel-Aviv, Israel
April 7, 2022

 

 

 

 

Exhibit 107

 

Calculation of Filing Fee Table

 

Form S-8

(Form Type)

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

Security Type  Security Class Title 

Fee
Calculation

Rule

  Amount
Registered(1)		   Proposed
Maximum
Offering Price
Per Share		   Maximum
Aggregate
Offering
Price		   Fee Rate   Amount of
Registration
Fee		 
Equity  Ordinary shares, no par value per share, issuable upon exercise of options outstanding pursuant to the 2016 Share Incentive Plan (the “2016 Plan”)  Other   6,159,593   $4.99(2)  $30,736,369.10    0.0000927   $2,850 
Equity  Ordinary shares, no par value per share, issuable upon settlement of restricted share unit awards outstanding pursuant to the 2016 Plan  Other   1,028,150   $11.32(3)  $11,638,658    0.0000927   $1,079 
Equity  Ordinary shares, no par value per share, issuable upon exercise of options outstanding pursuant to the 2021 Share Incentive Plan (the “2021 Plan”)  Other   736,274   $10.92(4)  $8,040,112.08    0.0000927   $746 
Equity  Ordinary shares, no par value per share, issuable upon settlement of restricted share unit awards outstanding pursuant to the 2021 Plan  Other   105,529   $11.32(3)  $1,194,588.28    0.0000927   $111 
Equity  Ordinary shares, no par value per share, reserved for issuance pursuant to the 2021 Plan  Other   14,592,550   $11.32(3)  $165,187,666    0.0000927   $15,313 
Equity  Ordinary shares, no par value per share, reserved for future issuance under the 2021 Employee Share Purchase Plan (the “ESPP”)  Other   1,285,699   $9.70(5)  $12,471,280.3    0.0000927   $1,157 
Total Offering Amounts    $229,268,673.76        $21,256 
Total Fee Offsets               — 
Net Fee Due              $21,256 

 

(1) This Registration Statement on Form S-8 (this “Registration Statement”) covers ordinary shares, no par value (“Ordinary Shares”), of Alpha Tau Medical Ltd. (the “Company” or the “Registrant”) that are (i) authorized for issuance under the 2021 Plan and the ESPP, and (ii) authorized for issuance upon the exercise of outstanding options issued pursuant to the Alpha Tau Medical Ltd. 2016 Plan (the “2016 Plan,” together with the 2021 Plan and the ESPP, the “Plans”). In the event of any share dividend, share split or other similar transaction involving the Ordinary Shares, the number of shares registered hereby shall automatically be adjusted in accordance with Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”).
   
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The Proposed Maximum Offering Price Per Share is calculated based on $4.99, which is the weighted average exercise price for options to purchase ordinary shares outstanding under the 2016 Plan.
   
(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The Proposed Maximum Offering Price Per Share is based on the average of the high ($12.14) and the low ($10.50) price of the Registrant’s ordinary shares as reported on the Nasdaq Capital Market on April 1, 2022.
   
(4) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The Proposed Maximum Offering Price Per Share is calculated based on $$10.92, which is the exercise price for options to purchase ordinary shares outstanding under the 2021 Plan.
   
(5) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The Proposed Maximum Offering Price Per Share is based 85% of the average of the high ($12.14) and the low ($10.50) price of the Registrant’s ordinary shares as reported on the Nasdaq Capital Market on April 1, 2022. Pursuant to the ESPP, the purchase price of the Ordinary Shares reserved for issuance thereunder will be at least 85% of the lower of the fair market value of the Registrant’s Ordinary Shares on the first trading day of the offering period and the last day of trading of the offering period.